Speakers
Corinne
Solier, Ph.D.
Leader, Clinical
Protein Biomarkers
Roche
Stacey
House, M.D.
Division of Emergency
Medicine, Washington
University in St. Louis
School of Medicine
Ultrasensitive
Immunoassays for
Translation of Biomarkers
from Discovery to the Clinic
Webinars
Free Registration!
www.GENengnews.com/biomarkers
Lynn R.
Zieske, Ph.D.
Vice President
Commercial Solutions
Singulex
Translating basic research into the clinic requires simple, fast,
and cost-efective technologies for biomarker screening and identi-
What You Will Learn
n
How Erenna technology can improve the sensitivity
over conventional ELISA assays by up to three orders
of magnitude
n
How Erenna technology can improve quantifcation
of critical low abundance analytes
n
How the Erenna System enables high sensitivity assays,
such as cytokine assays, in various matrices
n
How ultrasensitive high defnition immunoassays
can translate biomarkers into a clinical setting
n
How the Erenna System enables fexible and fast
assay development
n
How Erenna assays allow low volume consumption
enabling multiple measurements
fcation from disease characterization to drug development.
Singulex' proprietary single-molecule counting immunoassay
technology helps overcome challenges in the translation of protein
Moderator
biomarkers to the clinic. Its improved precision has enabled the
measurement of endogenous biomarker concentrations at
femtogram levels and precise monitoring over time.
The Singulex Erenna platform uses paramagnetic microparticles
as the solid-phase support for immune capture and a digital counting
system that detects single molecules as they pass through an interrogation space via capillary fow. This detection system results in a
John Sterling
Editor in Chief
GEN
count of discreet detection events above background rather than
a sum of total fuorescence including background.
In the webinar, participants will discuss the use of Erenna technology in serial testing of the cardiac biomarker troponin I (cTnI),
DATE
the standard of care for patients under evaluation for acute coro-
View it Now
On Demand
discussed will be the comparative performance of the Singulex
60 minutes
IL-17A research use only Assay to conventional assays for detection
COST
of this biomarker in rheumatoid arthritis patients and the validation
Complimentary
of this platform for use in clinical trials.
n
Biomarker researchers and developers
Drug developers
n Immunologists
n Researchers interested in advances
in immunoassay technologies
n
nary syndromes and now employed for the monitoring of chronic
DURATION
Who Should Attend
cardiovascular disease by the Singulex Clinical Laboratory. Also
Produced with support from